The high efficiency of actinic keratosis treatment, the availability of a variety of actinic keratosis treatments worldwide, which provides patients with a variety of options, and the increasing focus of market players on obtaining product approvals for the treatment of actinic keratosis from regulatory bodies are expected to drive the growth of the global actinic keratosis market over the forecast period. The rising number of generic product releases by industry leaders is likely to propel the global actinic keratosis market forward. For example, Perrigo Company plc, a healthcare business, introduced Diclofenac sodium gel, 3% in November 2018, a generic version of Solaraze Gel, 3% (diclofenac sodium gel, 3%). The topical treatment of actinic keratosis with Solaraze Gel, 3% is suggested. The expansion of the global actinic keratosis market is projected to be restricted in the near future due to the negative effects of the treatments used for actinic keratosis. During the projected period, the worldwide actinic keratosis market was negatively impacted by the Coronavirus (COVID-19) pandemic.
According to Coherent Market Insights, global Actinic Keratosis Market is estimated to be valued at US$ 8,070.0 Mn in 2022 and expected to exhibit a CAGR of 4.7% over the forecast period (2022-2030).
Prominent Companiesin the Actinic Keratosis Industry:
1. Almirall, S.A.
Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
2. Bausch Health Companies Inc.
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. Bausch Health Companies Inc. is headquartered in Laval, Canada.
3. Perrigo Company plc.
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
4. Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. the company was founded in 1983 and is based in Mumbai, India.
5. Bioforntera AG
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
6. Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.
7. Athenex, Inc.
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York. It also Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis.
8. 3M
3M Company provides diversified technology services in the United States and internationally. The company operates through four segments: Safety and Industrial; Transportation and Electronics; Health Care; and Consumer. 3M Company was founded in 1902 and is headquartered in St. Paul, Minnesota.
9. Mayne Pharma Group Limited
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
*Definition - Actinic Keratosis is skin damage induced by excessive sun exposure. Skin cancer is frequently preceded by actinic keratosis. Actinic keratosis is a chronic condition in which the majority of patients have recurring lesions over time.
